Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HINT1 | P49773 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.56 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.56 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.55 |
| ▸ | KRAS | P01116 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533806 | 1.00 | NT5E (0.64) | NT5EADORA1TGM2HPGDHINT1 | |
| SCHEMBL11327141 | 0.94 | NT5E (0.63) | NT5EADORA1TGM2HPGDHINT1 | |
| SCHEMBL29392340 | 0.93 | TAS1R3 (0.58) | NT5EADORA1TGM2HPGDHINT1 | |
| SCHEMBL1445061 | 0.93 | TGM2 (0.60) | NT5EADORA1TGM2HPGDHINT1 | |
| SCHEMBL1445069 | 0.93 | TGM2 (0.60) | NT5EADORA1TGM2HPGDHINT1 | |
| SCHEMBL17586739 | 0.93 | NT5E (0.69) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL2315499 | 0.93 | NT5E (0.69) | NT5ETGM2HINT1IMPDH2IMPDH1 | |
| SCHEMBL1971274 | 0.93 | NT5E (0.64) | NT5EADORA1TGM2HINT1IMPDH2 | |
| SCHEMBL2220159 | 0.93 | ADORA1 (0.67) | NT5EADORA1TGM2HPGDHINT1 | |
| SCHEMBL1971280 | 0.93 | NT5E (0.64) | NT5EADORA1TGM2HINT1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3816176-B1 | HYDRATE CRYSTAL OF 3',3'-CGAMP | YAMASA CORP (JP) | 2026-03-04 | — | — | EP | claimed |
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | SHANGHAI JUNSHI BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | claimed |
| US-20250250573-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-08-07 | — | — | US | claimed |
| EP-4594484-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4569114-A2 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4568682-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| US-20250188464-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-06-12 | — | — | US | claimed |
| US-20250188465-A1 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-06-12 | — | — | US | claimed |
| CN-120077134-A | APOC 3-targeted polynucleic acid molecule and application thereof | 靖因药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| EP-1501938-B1 | ANALYSIS OF SUBSTRATE UTILIZATION BY ANIMAL OR PLANT CELLS | BIOLOG INC (US) | 2009-10-21 | — | — | EP | claimed |
| EP-1401500-A4 | NUCLEOTIDE COMPOUNDS THAT BLOCK THE BITTER TASTE OF ORAL COMPOSITIONS | LINGUAGEN CORP (US) | 2006-06-14 | — | — | EP | claimed |
| US-6727076-B2 | UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES | BIOLOG, INC. | 2004-04-27 | — | — | US | claimed |
| EP-1401500-A1 | NUCLEOTIDE COMPOUNDS THAT BLOCK THE BITTER TASTE OF ORAL COMPOSITIONS | Linguagen Corp. (US) | 2004-03-31 | — | — | EP | claimed |
| WO-2004019885-A2 | FAST DISSOLVING FILM DELIVERY OF NUCLEOTIDES THAT INHIBIT THE UNPLEASANT TASTE OF BITTER TASTING MEDICATIONS | LINGUAGEN CORP. (US) | 2004-03-11 | — | — | WO | claimed |
| US-20030162164-A1 | Comparative phenotype analysis of cells, including testing of biologically active compounds | BIOLOG, INC. | 2003-08-28 | — | — | US | claimed |
| WO-2002096464-A1 | NUCLEOTIDE COMPOUNDS THAT BLOCK THE BITTER TASTE OF ORAL COMPOSITIONS | LINGUAGEN CORP. (US) | 2002-12-05 | — | — | WO | claimed |
| US-20020177576-A1 | Nucleotide compounds that block the bitter taste of oral compositions | REDPOINT BIO CORPORATION | 2002-11-28 | — | — | US | claimed |
| US-6472201-B1 | GROWING AND TESTING MICROORGANISMS IN A MULTITEST FORMAT WHICH UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES | BIOLOG, INC. | 2002-10-29 | — | — | US | claimed |
| US-4577012-A | ABSORPTION ON ACTIVATED CARBON, ELUTION WITH ALKALI HYDROXIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177576-A1 | Nucleotide compounds that block the bitter taste of oral compositions | NUDT1, P2RY1, TAS2R40 | NT5E 48/4885ADORA1 70/4885TGM2 3218/4885 |
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | TEK, TIE1, PCSK9 | NT5E 2645/4885ADORA1 4077/4885TGM2 2572/4885 |
| US-20250188464-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LPL, LDLR, PNLIP | NT5E 101/4885ADORA1 1203/4885TGM2 3834/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | NT5E 202/4885ADORA1 935/4885TGM2 3293/4885 |
| US-20250250573-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | F13B, F13A1, F12 | NT5E 113/4885ADORA1 2664/4885TGM2 3197/4885 |
| US-20250188465-A1 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | APOB, APOL1, NOP10 | NT5E 271/4885ADORA1 3557/4885TGM2 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.